Does DURVALUMAB Cause Malignant neoplasm progression? 1,330 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 1,330 reports of Malignant neoplasm progression have been filed in association with DURVALUMAB (IMFINZI). This represents 7.8% of all adverse event reports for DURVALUMAB.
1,330
Reports of Malignant neoplasm progression with DURVALUMAB
7.8%
of all DURVALUMAB reports
343
Deaths
166
Hospitalizations
How Dangerous Is Malignant neoplasm progression From DURVALUMAB?
Of the 1,330 reports, 343 (25.8%) resulted in death, 166 (12.5%) required hospitalization, and 49 (3.7%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for DURVALUMAB. However, 1,330 reports have been filed with the FAERS database.
What Other Side Effects Does DURVALUMAB Cause?
Death (2,817)
Pneumonitis (827)
Radiation pneumonitis (786)
Pyrexia (573)
Diarrhoea (530)
Pneumonia (453)
Dyspnoea (444)
Interstitial lung disease (430)
Off label use (395)
Fatigue (367)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which DURVALUMAB Alternatives Have Lower Malignant neoplasm progression Risk?
DURVALUMAB vs DUTASTERIDE
DURVALUMAB vs DUTASTERIDE\TAMSULOSIN
DURVALUMAB vs DUVELISIB
DURVALUMAB vs DYDROGESTERONE
DURVALUMAB vs EBASTINE